Review
Nature Reviews Cancer 2, 727-739 (October 2002) | doi:10.1038/nrc905
Clinical translation of angiogenesis inhibitors
See also: Correspondence by Millar
Robert Kerbel1 & Judah Folkman2 About the authors
Abstract
Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply. The successful translation of angiogenesis inhibitors to clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians. What are the most common questions that clinicians ask as they begin to test angiogenesis inhibitors in cancer clinical trials?
- View At a Glance
Author affiliations
-
Molecular and Cellular Biology Research, Sunnybrook and Women's College Health Sciences Centre, S-218, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.
Email: robert.kerbel@swchsc.on.ca -
Department of Surgery, Children's Hosptial, 300 Longwood Avenue, Boston, Massachusetts 02115, USA.
Email: judah.folkman@tch.harvard.edu
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated NEWS AND VIEWS RESEARCH |
